Page 22 - Read Online

Page 16 of 17 Peng et al. Microbiome Res Rep 2024;3:5 https://dx.doi.org/10.20517/mrr.2023.47

68. Han JX, Tao ZH, Wang JL, et al. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on
colorectal cancer. Nat Microbiol 2023;8:919-33. DOI
69. Zhang W, Mao S, Shi D, et al. MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by
targeting indoleamine 2,3-dioxygenase 1. Front Oncol 2019;9:619. DOI PubMed PMC
70. Lee SH, Mahendran R, Tham SM, et al. Tryptophan-kynurenine ratio as a biomarker of bladder cancer. BJU Int 2021;127:445-53.
DOI PubMed
71. Wang R, Kang H, Zhang X, et al. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS. BMC
Cancer 2022;22:214. DOI PubMed PMC
72. Lai CR, Wang HH, Chang HH, et al. Enhancement of farnesoid x receptor inhibits migration, adhesion and angiogenesis through
proteasome degradation and VEGF reduction in bladder cancers. Int J Mol Sci 2022;23:5259. DOI PubMed PMC
73. Lai CR, Tsai YL, Tsai WC, et al. Farnesoid X receptor overexpression decreases the migration, invasion and angiogenesis of human
bladder cancers via AMPK activation and cholesterol biosynthesis inhibition. Cancers 2022;14:4398. DOI PubMed PMC
74. Wang H, Rong X, Zhao G, et al. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative
breast cancer. Cell Metab 2022;34:581-94.e8. DOI
75. Mirji G, Worth A, Bhat SA, et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to
immune checkpoint blockade in pancreatic cancer. Sci Immunol 2022;7:eabn0704. DOI PubMed PMC
+
76. Luu M, Riester Z, Baldrich A, et al. Microbial short-chain fatty acids modulate CD8 T cell responses and improve adoptive
immunotherapy for cancer. Nat Commun 2021;12:4077. DOI PubMed PMC
77. Szarvas T, vom Dorp F, Ergün S, Rübben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev
Urol 2011;8:241-54. DOI PubMed
78. Minoli M, Cantore T, Hanhart D, et al. Bladder cancer organoids as a functional system to model different disease stages and therapy
response. Nat Commun 2023;14:2214. DOI PubMed PMC
79. Goubet AG, Rouanne M, Derosa L, Kroemer G, Zitvogel L. From mucosal infection to successful cancer immunotherapy. Nat Rev
Urol 2023;20:682-700. DOI PubMed
80. Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the
chemotherapeutic drug gemcitabine. Science 2017;357:1156-60. DOI PubMed PMC
81. Compérat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments.
Lancet 2022;400:1712-21. DOI
82. Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a
clinical perspective. Nat Rev Urol 2022;19:280-94. DOI PubMed
83. Aso Y, Akazan H. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urol Int
1992;49:125-9. DOI PubMed
84. Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer
in a double-blind trial. Eur Urol 1995;27:104-9. DOI PubMed
85. Herr H, Donat M. Reduced recurrence of low-grade papillary bladder tumors associated with asymptomatic bacteriuria. Urology
2019;124:179-82. DOI PubMed
86. Zeng J, Zhang G, Chen C, et al. Alterations in urobiome in patients with bladder cancer and implications for clinical outcome: a
single-institution study. Front Cell Infect Microbiol 2020;10:555508. DOI PubMed PMC
87. James C, Gomez K, Desai S, et al. Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in
patients with non-muscle invasive bladder cancer. Front Cell Infect Microbiol 2023;13:1125809. DOI PubMed PMC
88. Integrative HMP (iHMP) Research Network Consortium. The integrative human microbiome project. Nature 2019;569:641-8. DOI
PubMed PMC
89. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 2018;15:615-25.
DOI PubMed
90. Knorr J, Werneburg G, Adler A, et al. PD12-01 bladder tumor microbiome may augment response to BCG in non-muscle invasive
bladder cancer. J Urol 2022;207:e195. DOI
91. Knorr J, Adler A, Agudelo J, et al. PD42-04 tumor microbiome associated with BCG response in non-muscle invasive bladder cancer.
J Urol 2021;206:e725-6. DOI
92. Hussein AA, Elsayed AS, Durrani M, et al. Investigating the association between the urinary microbiome and bladder cancer: an
exploratory study. Urol Oncol 2021;39:370.e9-19. DOI PubMed
93. Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed
Pharmacother 2020;129:110393. DOI
94. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell
2021;184:5309-37. DOI PubMed PMC
95. Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun
2021;26:100296. DOI PubMed
96. Siefker-Radtke A, Curti B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol
2018;15:112-24. DOI PubMed
97. Cathomas R, Lorch A, Bruins HM, et al. The 2021 updated european association of urology guidelines on metastatic urothelial